OR WAIT null SECS
July 25, 2024
BeiGene has invested $800 million into a new biologics manufacturing facility in Hopewell, NJ, which also houses its clinical R&D capabilities.
June 26, 2024
Novo Nordisk plans to invest $4.1 billion in a second fill/finish manufacturing facility in Clayton, N.C., boosting its current 2024 investments into production to $6.8 billion.
June 11, 2024
AGC Biologics has completed an expansion at its Copenhagen, Denmark, site, which doubles its bioreactor capacity for mammalian-based cell culture.
June 07, 2024
FUJIFILM Diosynth Biotechnologies CEO Lars Petersen highlights the company’s strategic goals and meeting market demand for mammalian cell culture capacity.
May 21, 2024
This new facility will allow AstraZeneca to offer full manufacturing processing for antibody drug conjugates.
March 25, 2024
With the Vacaville, Calif., site acquisition, Lonza gains one of the largest biologics manufacturing sites for mammalian cell-based therapeutics.
February 22, 2024
Daiichi Sankyo is investing approximately €1 billiion (US$1.08 billion) to expand its Pfaffenhofen an der Ilm, Germany, site for ADC development and production.
January 30, 2024
IMU Biosciences has secured £11.5 million in its Series A financing round.
January 16, 2024
CellVoyant has raised £7.6 million in seed funding to speed up the development of novel cell therapies.
January 15, 2024
Boehringer Ingelheim is investing €120 million (US$131 million) into its Koropi, Greece site to expand production for new therapeutics.